Superiority of rapamycin over tacrolimus in preserving nonhuman primate treg half-life and phenotype after adoptive transfer

American Journal of Transplantation

Volumn 14, Issue 12, 2014, Pages 2691-2703

  Singh, K ^a   Stempora, L ^a   Harvey, R D ^b   Kirk, A D ^a   Larsen, C P ^a   Blazar, B R ^c   Kean, L S ^b,d  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Basic (laboratory) research science; immunobiology; immunosuppression immune modulation; lymphocyte biology: trafficking; T cell biology; tolerance: experimental; translational research science

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD4 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; 5-(6)-CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; FORKHEAD TRANSCRIPTION FACTOR; IMMUNOSUPPRESSIVE AGENT; SUCCINIMIDE DERIVATIVE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CELL MIGRATION; CELL POPULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG INFUSION; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HALF LIFE TIME; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MIXED LYMPHOCYTE REACTION; NONHUMAN; PHENOTYPE; PRIMATE; REGULATORY T LYMPHOCYTE; RHESUS MONKEY; ANIMAL; AUTOTRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; TISSUE DISTRIBUTION; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; FLOW CYTOMETRY; FLUORESCEINS; FLUORESCENT DYES; FORKHEAD TRANSCRIPTION FACTORS; HALF-LIFE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MACACA MULATTA; PHENOTYPE; SIROLIMUS; SUCCINIMIDES; T-LYMPHOCYTES, REGULATORY; TACROLIMUS; TISSUE DISTRIBUTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84910648204     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12934     Document Type: Article

References (35)

1. Steiner D, Brunicki N, Bachar-Lustig E, Taylor PA, Blazar BR, Reisner Y., Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and rapamycin. Exp Hematol 2006; 34: 802-808.
2. Rodriguez-Garcia M, Boros P, Bromberg JS, Ochando JC., Immunotherapy with myeloid cells for tolerance induction. Curr Opin Organ Transplant 2010; 15: 416-421.
3. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H., Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010; 90: 1312-1320.
4. Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, Wood K., Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 2010; 90: 1321-1327.
5. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 2011; 117: 1061-1070.
6. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-3928.
7. Sakaguchi S, Miyara M, Costantino CM, Hafler DA., FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490-500.
8. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T., Regulatory T cells: How do they suppress immune responses ? Int Immunol 2009; 21: 1105-1111.
9. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20-21.
10. Ding Y, Xu J, Bromberg JS., Regulatory T cell migration during an immune response. Trends Immunol 2012; 33: 174-180.
11. Itoh M, Takahashi T, Sakaguchi N, et al. Thymus and autoimmunity: Production of CD25+ CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999; 162: 5317-5326.
12. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, et al. Administration of CD4+ CD25 high CD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care 2012; 35: 1817-1820.
13. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013; 5: 179ra43.
14. Taylor PA, Lees CJ, Blazar BR., The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.
15. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S., Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
16. Edinger M, Hoffmann P, Ermann J, et al. CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150.
17. Nguyen VH, Zeiser R, Dasilva DL, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007; 109: 2649-2656.
18. Singh K, Kozyr N, Stempora L, et al. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant 2012; 12: 1441-1457.
19. Anderson A, Martens CL, Hendrix R, et al. Expanded nonhuman primate tregs exhibit a unique gene expression signature and potently downregulate alloimmune responses. Am J Transplant 2008; 8: 2252-2264.
20. Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med 2011; 3: 83ra41.
21. Graziano M, St-Pierre Y, Beauchemin C, Desrosiers M, Potworowski EF., The fate of thymocytes labeled in vivo with CFSE. Exp Cell Res 1998; 240: 75-85.
22. Quah BJ, Warren HS, Parish CR., Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2007; 2: 2049-2056.
23. Quah BJ, Parish CR., New and improved methods for measuring lymphocyte proliferation in vitro and in vivo using CFSE-like fluorescent dyes. J Immunol Methods 2012; 379: 1-14.
24. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66: 10995-11004.
25. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010; 16: 1245-1256.
26. Bopp T, Palmetshofer A, Serfling E, et al. NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4+ T lymphocytes by CD4+ CD25+ regulatory T cells. J Exp Med 2005; 201: 181-187.
27. Karwot R, Ubel C, Bopp T, Schmitt E, Finotto S., Increased immunosuppressive function of CD4(+)CD25(+)Foxp3(+)GITR+ T regulatory cells from NFATc2((-/-)) mice controls allergen-induced experimental asthma. Immunobiology 2012; 217: 905-911.
28. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390-399.
29. Haxhinasto S, Mathis D, Benoist C., The AKT-mTOR axis regulates de novo differentiation of CD4+ Foxp3+ cells. J Exp Med 2008; 205: 565-574.
30. Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, mTOR. Proc Natl Acad Sci U S A 2008; 105: 7797-7802.
31. Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G, Nicolin A., Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur J Cancer 2001; 37: 2121-2128.
32. Hendrikx TK, Velthuis JH, Klepper M, et al. Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients. Transpl Int 2009; 22: 884-891.
33. Ma A, Qi S, Wang Z, et al. Combined therapy of CD4(+)CD25(+) regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice. Int Immunopharmacol 2009; 9: 553-563.
34. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+ CD25+ Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111: 453-462.
35. Coenen JJ, Koenen HJ, van Rijssen E, et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 2007; 39: 537-545.